Patent · US Active

Imidazopiperazine inhibitors of transcription activating proteins

US11058688B2 · kind B2 · utility

1Cited by
4References
41Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 29, 2019
Grant dateJul 13, 2021
Priority date
Expiry dateMar 29, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.